Medexus Pharmaceuticals Inc. is a Canada-based rare disease pharmaceutical company. The Company is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The Company is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The Company's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. It also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.